Liposomal dry powders as aerosols for pulmonary delivery of proteins

被引：46

作者：

Lu D. ^{[1
]}

Hickey A.J. ^{[1
]}

机构：

[1] School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill

来源：

AAPS PharmSciTech | / 6卷 / 4期

基金：

美国国家卫生研究院;

关键词：

Aerosol; Dry powders; Liposome; Lyophilization; Protein; Pulmonary delivery;

D O I：

10.1208/pt060480

中图分类号：

学科分类号：

摘要：

The purpose of this research was to develop liposomal dry powder aerosols for protein delivery. The delivery of stable protein formulations is essential for protein subunit vaccine delivery, which requires local delivery to macrophages in the lungs. β-Glucuronidase (GUS) was used as a model protein to evaluate dry powder liposomes as inhaled delivery vehicles. Dimyristoyl phosphatylcholine:cholesterol (7:3) was selected as the liposome composition. The lyophilization of liposomes, micronization of the powders, aerosolization using a dry powder inhaler (DPI), and in vitro aerodynamic fine particle fraction upon collection in a twin-stage liquid impinger were evaluated. After lyophilization and jet-milling, the total amount of GUS and its activity, representing encapsulation efficiency and stability, were evaluated. The GUS amount and activity were measured and compared with freshly-prepared liposomes in the presence of mannitol, 43% of initial GUS amount, 29% of GUS activity after lyophilization and 36% of GUS amount, 22% of activity after micronization were obtained. Emitted doses from dry powder inhaler were 53%, 58%, 66%, and 73% for liposome powder:mannitol carrier ratios of 1:0, 1:4,1:9, and 1:19. Fifteen percent of the liposome particles were less than 6.4 μm in aerodynamic diameter. The results demonstrate that milled liposome powders containing protein molecules can be aerosolized effectively at a fixed flow rate. Influences of different cryoprotectants on lyophilization of protein liposome formulations are reported. The feasibility of using liposomal dry powder aerosols for protein delivery has been demonstrated but further optimization is required in the context of specific therapeutic proteins. Copyright © 2003. All Rights Reserved.

引用

页码：E641 / E648

页数：7

共 38 条

[1]

Ahmed T., Clinical testing of aerosol drugs, Respiratory Drug Delivery, pp. 208-242, (1990)

[2]

Schreier H., Gonzales-Rothi R.J., Stecenko A.A., Pulmonary delivery of liposomes, J Control Release, 24, pp. 209-223, (1993)

[3]

Zeng X.M., Mantin G.P., Marriott C., The controlled drug delivery to the lung, Int J Pharm, 124, pp. 149-164, (1995)

[4]

Gilbert B.E., Wyde P.R., Wilson S.Z., Robins R.K., Aerosol and intraperitoneal administration of ribavarin and ribavarin triacetate: Pharmacokinetics and protection of mice against intracerebral infection with influenza A/WDN virus, Antimicrob Agents Chemother, 35, pp. 1448-1453, (1991)

[5]

Parthasarathy R., Gilbert B., Mehta K., Aerosol delivery of liposomal all-trans retinoic acid to the lungs, Cancer Chemother Pharmacol, 43, pp. 277-283, (1999)

[6]

Suntres Z.E., Shek P.N., Alleviation of paraquat-induced lung injury by pretreatment with bifunctional liposomes containing α-tocopherol and glutathione, Biochem Pharmacol, 52, pp. 1515-1520, (1996)

[7]

Briscoe P., Caniggia I., Graves A., Et al., Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes, Am J Physiol, 268, (1995)

[8]

Thibeault D.W., Rezaiekhaligh M., Mabry S., Beringer T., Prevention of chronic pulmonary oxygen toxicity in young rats with liposome-encapsulated catalase administered intratracheally, Pediatr Pulmonol, 11, pp. 318-327, (1991)

[9]

Saari M., Vidgren M.T., Kiskinen M.O., Turjanmaa V.H.M., Neiminen M.M., Pulmonary distribution and clearance of 2 beclomethasone liposome formulations in healthy volunteers, Int J Pharm, 181, pp. 1-9, (1999)

[10]

Lange C.F., Hancock R.E.W., Samuel J., Finlay W.H., In vitro delivery and regional airway surface liquid concentration of a liposomal cationic peptide, J Pharm Sci, 90, pp. 1647-1657, (2001)

← 1 2 3 4 →